A
AnaptysBio D
D
ANAB
44.940
USD
-0.82
(-1.79%)
مغلق
حجم التداول
16,942
الربح لكل سهم
-2
العائد الربحي
-
P/E
-16
حجم السوق
1,244,319,842
الأخبار المقالات
العنوان: AnaptysBio
القطاع: Healthcare
الصناعة: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).